This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.

Inclusion Criteria:

• Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging;
• Age ≥18 years old, male or female;
• Patients receiving treatment based on irinotecan hydrochloride liposome injection II;
• The subjects voluntarily joined the study and signed the informed consent.

Exclusion Criteria:

• Confirmed pregnant or lactating women;
• The researchers determined that other conditions were not suitable for inclusion in the study.

Pancreatic cancer patients in China